GU Oncology Now Journal
Up to one-third of all UTUC patients present with variant histology, such as squamous or micropapillary features. Stereotactic body radiotherapy can benefit RCC patients deemed unfit for surgical therapy. 1 of 4 will UTUC patients will have a variant histologic subtype such as squamous cell, micropapillary, or neuroendocrine. The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes. Robert Uzzo gives an overview of the RENAL score that he developed, plus his outlook on the future of renal characterization. The history of robot-assisted laparoscopic & open radical prostatectomies are discussed with their outcomes and future uses. A study analyzing the safety and efficacy of large surface area microparticle docetaxel for NMIBC is reviewed. Bradley McGregor, MD gives an overview of his GU oncology career from his Air Force beginnings to his work at Dana-Farber. Dr. Catherine H. Marshall is interviewed on the use and future of chemotherapy for the treatment of advanced prostate cancer. A review of “A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers” from the CKCis. A guide to hereditary RCCs and their syndromes, as well as the relevant recommended guidelines for diagnosis and management. Integrated imaging with PET/CT has allowed clinicians to gain significant anatomical and oncologic information on tumors. Abiraterone acetate + prednisolone is compared to enzalutamide + AAP for mHSPC cancer starting androgen-deprivation therapy. Results from the phase 3 PROpel trial on abiraterone + olaparib vs abiraterone + placebo as first-line therapy for MCRPC Scott Eggener, MD gives an overview of focal therapy for prostate cancer, including its benefits and current research. Researchers evaluated the safety and efficacy of intravesical pembrolizumab when in conjunction with intravesical BCG. Dr. Preston C. Sprenkle, MD discusses his career beginnings in urology and interest in prostate ablation therapy research. Cell-based therapies have shown efficacy in disease settings, but for solid tumors, research has proceeded at a slower pace. Socioeconomic disadvantages, disparities, and equitable access in kidney and bladder cancer care are reviewed. According to a recent study, laparoscopic surgery may be equivalent to open surgery for performing partial nephrectomies.